initial public offerings (IPOs) trading on American exchanges

Thursday, December 12, 2013

Enzymotec (ENZY) began trading on the NASDAQ on 27 September 2013

  • Update: Enzymotec Ltd. (Nasdaq:ENZY) to be acquired by Frutarom (LSE:FRUT) (TASE:FRUT), an Israeli company, for $11.90 per share in cash.  (Oct. 29, 2017)


Enzymotec Ltd. is engaged in manufacturing of ingredients and medical foods company. Its technologies, research, and clinical validation process enables the Company to develop differentiated solutions across a variety of products. The Company markets its product portfolio primarily to established global consumer companies and target large and growing consumer health and wellness markets. Its clinically validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases. The Company operates in two segments: Nutrition and VAYA Pharma. In addition to its existing products, the Company has several other products to address additional indications in the development phase. enzyme processes; lipid modification; lipid analysis; and process technology and development.


Sagi 2000 Industrial Park, P.O. Box6

Key stats and ratios

Q2 (Jun '13)2012
Net profit margin15.57%12.14%
Operating margin16.18%14.04%
EBITD margin-17.79%
Return on average assets15.28%9.52%
Return on average equity3.98%3.19%

No comments:

Post a Comment